Hyaluronic +68% is the calendar. Peptide +39% is the signal.
Hyaluronic acid is the fastest-rising ingredient in our data at +68.2% over two months. It is also an ingredient that rises every October. Strip the seasonal swing out and the top of the list becomes peptide, +39.0% with a seasonal amplitude of only 2.4%.
Ranking ingredients by growth alone picks the wrong ingredient. In our daily Olive Young, Hwahae and NAVER data (updated 2 October 2026, change measured 5 August to 30 September), hyaluronic acid rose 68.2% and leads the list — but that ingredient has a 51.8% annual swing and starts climbing every October. Peptide rose 39.0% in the same window with an annual swing of just 2.4%. The rise the calendar cannot explain is the peptide one. And peptide is not on Korea's four-ingredient notified list for anti-wrinkle claims.
The fastest riser is hyaluronic acid, and that is because it is October
In our daily collection of Olive Young and Hwahae rankings and NAVER search indexes, the biggest ingredient move of the last two months (5 August to 30 September 2026) was hyaluronic acid, from 33.0 to 55.6, up 68.2%. Read that figure alone and the obvious conclusion is to build a hyaluronic range immediately.
The same dataset carries two more columns for each ingredient: its annual swing and the month it starts rising. Hyaluronic acid swings 51.8% across the year and begins climbing every October. The current rise is the ingredient doing what it always does, and after the January peak it gives the same amount back.
So the number a buyer needs is not how much something rose. It is how much of the rise the calendar does not explain. On a six-to-nine-month development timeline, chasing a seasonal climb puts your launch date on the downslope.
Strip the season out and peptide moves to the top
Placing growth and annual swing side by side reorders the list.
| Ingredient | 2-month change | Annual swing | Rising month | Reading |
|---|---|---|---|---|
| Hyaluronic acid | +68.2% | 51.8% | October | Seasonal |
| Peptide | +39.0% | 2.4% | August | Off-season |
| Panthenol | +24.6% | 91.1% | July | Seasonal |
| Retinol | +20.4% | 22.9% | October | Seasonal |
| Exosome | +19.7% | -12.7% | August | Off-season |
| PDRN | -15.4% | -4.3% | November | — |
| Niacinamide | -20.1% | — | — | — |
Peptide's annual swing is 2.4%. It is an ingredient that normally barely reacts to the calendar, which is why 39.0% in two months cannot be handed back to seasonality. Panthenol is the opposite case: a 91.1% swing with its peak in October means most of that +24.6% is the season.
Exosome is also an off-season rise, but there the label comes first — since January 2025 Korea has restricted the word used on its own. Demand and permitted wording are two separate checks. The daily movement of candidate ingredients is published on today's ingredient signals.
Demand is moving outside the notified list
This is where the numbers invert a second time. To put "anti-wrinkle" or "whitening" on a product in Korea you go through the functional cosmetics route, and Annex 4 of the Regulations on Functional Cosmetics Review names the ingredients that need no separate efficacy dossier. For anti-wrinkle there are four.
| Notified anti-wrinkle ingredient | Concentration |
|---|---|
| Retinol | 2,500 IU/g |
| Retinyl palmitate | 10,000 IU/g |
| Adenosine | 0.04% |
| Polyethoxylated retinamide | 0.05–0.2% |
Peptide is not on it. The whitening list of nine includes niacinamide at 2–5%, and niacinamide fell 20.1% in the same window. The ingredients the regulation has pre-cleared are losing attention, and an ingredient it has not pre-cleared is gaining it.
In practical terms: retinol gives you the short path to a claim and a signal tied to the calendar. Peptide gives you a live signal, but a functional claim means building the review data yourself — otherwise the product sells on the ingredient list without the claim. Either way it is a decision to make before the quotation, not after.
PDRN is cooling, and still on the shelf
The PDRN demand index fell 15.4% over the same two months. On the shelf, though, it has not left; it has moved position. A PDRN pore mask set (3+2 sheets, KRW 20,400) came in as a category number one in the October Olive Young picks, and the pad set that held a top-20 place for 64 consecutive days (KRW 26,200) now includes PDRN pads as a giveaway.
Ingredients tend to age in that order. First the product name, then a supporting position, then the free add-on inside a bundle. PDRN is somewhere between the second and third step. Too late to build a new hero product around, still useful as the component that makes a bundle worth its price.
In short
- Our data (updated 2 October 2026, change window 5 August to 30 September) puts hyaluronic acid first at +68.2% — with a 51.8% annual swing and October as its rising month, which makes it seasonal
- Strip the season out and peptide leads at +39.0% on a 2.4% annual swing, followed by exosome at +19.7%
- Peptide is not one of the four notified anti-wrinkle ingredients, so a functional claim requires your own review data
- Niacinamide, which is notified for whitening, fell 20.1% in the same window — demand is moving off the pre-cleared path
- PDRN is down 15.4% and is moving from product name to bundled add-on
Once the ingredient is settled, the product planner returns an estimated cost and a sample brief within a day.
*Sources: Ministry of Food and Drug Safety, Regulations on Functional Cosmetics Review, Annex 4 (categories exempt from data submission) — four anti-wrinkle and nine whitening ingredients with concentrations, per published Korean-language summaries of the annex. The exosome labelling restriction is from the MFDS cosmetics labelling and advertising guidance revised January 2025. Ingredient demand indexes, seasonal amplitudes and shelf rankings come from our own daily collection of Olive Young, Hwahae and NAVER DataLab (updated 2 October 2026 09:40 KST; collection window 16 July to 1 October 2026, 68 days; change window 5 August to 30 September). Search indexes are share-of-click measures, not absolute volumes.*
Questions people ask
Not on its own. Put the seasonal amplitude next to the growth figure. Hyaluronic acid is up 68.2% over two months, but its annual swing is 51.8% and its rising month is October, so the climb is what it does every year — and it gives the same amount back after the January peak. Peptide's annual swing is 2.4%, which leaves almost nothing for the calendar to explain. The same +39% means something different depending on that column.
In our data, peptide (+39.0%) and exosome (+19.7%) are the two rises the calendar does not account for. Exosome comes with a labelling problem first: since January 2025 Korea does not allow the word on its own, so the label has to be designed before the formula. Peptide has no labelling restriction, but a wrinkle-improvement functional claim requires you to generate your own review data. In both cases there is a step between "there is demand" and "we can sell it".
It can, but not through the documentation-waiver route. Annex 4 of the Regulations on Functional Cosmetics Review lists exactly four anti-wrinkle ingredients: retinol at 2,500 IU/g, retinyl palmitate at 10,000 IU/g, adenosine at 0.04%, and polyethoxylated retinamide at 0.05–0.2%. Peptide is not among them. Using the claim means preparing individual review data, which adds both time and cost to the launch plan.
The demand index is falling, but on the shelf its role is changing rather than disappearing. PDRN is down 15.4% in the same window. Meanwhile a PDRN pore mask set (3+2 sheets, KRW 20,400) entered as a category number one in the October Olive Young picks, and the pad set that held the top 20 for 64 straight days (KRW 26,200) carries PDRN pads as the free add-on. That is the move from headline ingredient to component.
That demand is moving away from the notified ingredients. Niacinamide sits on Korea's whitening notified list at 2–5%, which means a claim can be made without extra documentation — and it fell 20.1% in the same window. Peptide, which is on no list, rose 39.0%. Consumer attention is moving off the path the regulation has already cleared.